Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on November 29, 2018. The report discloses a specific corporate event regarding the unregistered sale of equity securities.
Key Financial Metrics
The filing details a capital raise transaction but does not provide comprehensive financial statements such as revenue, profit, cash flow, or debt levels.
- Capital Raised: $2.5 million
- Shares Issued: 1,879,700 shares of Class A common stock
- Price Per Share: $1.33
- Investor: MacAndrews & Forbes Group LLC
Material Changes
The material change reported is the execution of a definitive agreement under the "2018 Letter Agreement" dated July 30, 2018. The Company exercised its right to require the Investor to purchase the aforementioned shares, resulting in an immediate increase in equity capital.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the transaction is qualified by reference to the 2018 Letter Agreement (Exhibit 10.1 to the November 8, 2018 Form 10-Q). The filing text does not provide a clear value for any unusual items or contingencies outside of this equity transaction.
Investor Verification Checklist
- Verify the terms of the "2018 Letter Agreement" referenced in Exhibit 10.1 of the November 8, 2018 Form 10-Q.
- Confirm the total number of outstanding shares post-transaction to assess dilution impact.
- Review the Company's cash position in the most recent 10-Q to understand the liquidity impact of the $2.5 million infusion.
- Check for any subsequent filings regarding the use of proceeds from this capital raise.